A randomized study investigating the effect of omeprazole on the pharmacokinetics of oral semaglutide.

Bækdal TA, Breitschaft A, Navarria A, Hansen CW

Expert opinion on drug metabolism & toxicology30 Jun 2018Cited by 48 (Europe PMC)

PMID29897249DOI10.1080/17425255.2018.1488965PepBankPUB-29897249

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

2 results from studies that gave the peptide. 2 results from people.

01HumanRandomized controlled trialPharmacokinetics
In healthy subjects, omeprazole co-administration did not significantly change oral semaglutide AUC0-24h at day 10 (ratio 1.13, 90%CI 0.88, 1.45).
In plain wordsIn healthy people, taking omeprazole with oral semaglutide did not significantly change how much semaglutide was absorbed, compared with oral semaglutide alone.
Peptide
Semaglutide
Outcome
No significant changeSemaglutide AUC0-24h at day 10
Study
n = 54
Comparator
Oral semaglutide alone
Analysis
Primary
Outcome group
Pharmacokinetics · Pharmacology
Studied dose
Dose not stated · oralAs given in this study (human).
Measurements
AUC0-24h treatment ratio
1.13 ratio
oral semaglutide plus omeprazole vs alone
Source sentences
Summary
Exposure of semaglutide appeared to be slightly increased, although not statistically significantly, with oral semaglutide plus omeprazole versus oral semaglutide alone (AUC_{0-24h,semaglutide,Day10} [estimated treatment ratio 1.13; 90%CI 0.88, 1.45] and C_{max,semaglutide,Day10} [es…
1 context sentence(design, population, supporting numbers)
Summary · context
A single-center, randomized, open-label, parallel-group trial investigated pharmacokinetic interactions of oral semaglutide with omeprazole (40 mg once-daily) in 54 healthy subjects.
Report a problemFND-2989724901
02HumanRandomized controlled trialPharmacokinetics
In healthy subjects, omeprazole co-administration did not significantly change oral semaglutide Cmax at day 10 (ratio 1.16, 90%CI 0.90, 1.49).
In plain wordsIn healthy people, omeprazole did not significantly change the peak semaglutide level after oral semaglutide, compared with oral semaglutide alone.
Peptide
Semaglutide
Outcome
No significant changeSemaglutide Cmax at day 10
Study
n = 54
Comparator
Oral semaglutide alone
Analysis
Primary
Outcome group
Pharmacokinetics · Pharmacology
Studied dose
Dose not stated · oralAs given in this study (human).
Measurements
Cmax treatment ratio
1.16 ratio
oral semaglutide plus omeprazole vs alone
Source sentences
Summary
Exposure of semaglutide appeared to be slightly increased, although not statistically significantly, with oral semaglutide plus omeprazole versus oral semaglutide alone (AUC_{0-24h,semaglutide,Day10} [estimated treatment ratio 1.13; 90%CI 0.88, 1.45] and C_{max,semaglutide,Day10} [es…
1 context sentence(design, population, supporting numbers)
Summary · context
A single-center, randomized, open-label, parallel-group trial investigated pharmacokinetic interactions of oral semaglutide with omeprazole (40 mg once-daily) in 54 healthy subjects.
Report a problemFND-2989724902

Studies that did not test the peptide alone2

In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Semaglutide.

03HumanNot a test of Semaglutide aloneRandomized controlled trialMechanism
In healthy subjects, gastric pH was higher with oral semaglutide plus omeprazole than with oral semaglutide alone.
In plain wordsIn healthy people, stomach pH was higher with omeprazole added to oral semaglutide than with oral semaglutide alone.
Peptide
Semaglutide
Outcome
IncreaseGastric pH
Study
n = 54
Comparator
Oral semaglutide alone
Outcome group
Pharmacokinetics · Pharmacology
Source sentences
Summary
Gastric pH was higher with oral semaglutide and omeprazole versus oral semaglutide alone.
1 context sentence(design, population, supporting numbers)
Summary · context
A single-center, randomized, open-label, parallel-group trial investigated pharmacokinetic interactions of oral semaglutide with omeprazole (40 mg once-daily) in 54 healthy subjects.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-2989724903
04HumanNot a test of Semaglutide aloneRandomized controlled trialSafety outcome
In healthy subjects, adverse events with oral semaglutide and omeprazole were mild or moderate and mostly gastrointestinal.
In plain wordsIn healthy people, side effects were mild or moderate and mostly affected the digestive system.
Peptide
Semaglutide
Outcome
Not applicableAdverse events
Study
n = 54
Outcome group
Adverse events · Gastrointestinal
Source sentences
Summary
Adverse events were mild or moderate and, most commonly, gastrointestinal disorders.
1 context sentence(design, population, supporting numbers)
Summary · context
A single-center, randomized, open-label, parallel-group trial investigated pharmacokinetic interactions of oral semaglutide with omeprazole (40 mg once-daily) in 54 healthy subjects.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-2989724904

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 1NCT02249871

Investigating the Influence of Omeprazole on the Pharmacokinetics of Oral Semaglutide in Healthy Subjects

Novo Nordisk A/Sn = 5424 Sept 2014 to 1 Apr 2015

Diabetes · Healthy

Trial page ClinicalTrials.govUpdated 13 Aug 2018

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
11 Oct 2026, 00:50 UTC
Study results updated
Version 1
9 Oct 2026, 03:06 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.